Immunovant to Merge with Health Sciences Acquisitions Corporation, Creating New Publicly Listed FcRn-Focused Company – Top shareholders of Immunovant post-closing to include Roivant Sciences and blue-chip biotech investors, including RTW Investments, BVF Partners, Adage Capital Management, Cormorant Asset Management, Eventide Asset Management, and Perceptive Advisors – Immunovant is developing IMVT-1401, a fully human antibody to FcRn that delivered a mean IgG reduction of nearly 80% in a Phase 1 study of healthy volunteers receiving 4 weekly 680 mg subcutaneous injections – Immunovant is expected to have more than $100 million at closing to fund development of IMVT-1401 into 2H 2021 – Top-line data from ongoing Phase 2a trial in Graves’ ophthalmopathy expected by Q1 2020 – Top-line data from ongoing Phase 2a trial in myasthenia gravis expected by Q2 2020 PR Newswire NEW YORK and LONDON, Oct. 2, 2019 NEW YORK and LONDON , Oct. 2, 2019 /PRNewswire/ — Health Sciences Acquisitions Corporation (“HSAC,” NASDAQ: HSAC), a special purpose acquisition company sponsored by RTW Investments, and Immunovant Sciences Ltd. […]
